Angelalign Technology reported a 42.9% revenue increase to $230.7 million and a 79.6% net profit rise for H1 2026, with the board declaring a $100 million interim dividend amid international market gains.
Align Technology will add three independent directors to its board and raise its 2026 share repurchase target to $400–$500 million, following talks with Elliott Investment Management. A strategic review is also underway.
As the clear aligner manufacturer expands its domestic manufacturing and U.S. market presence, Vice President Jason Tabb explains how a reliance on long-term clinical feedback is driving the company's strategy.
The AAO is holding its annual Smiles at 7 Day on July 7, encouraging early orthodontic evaluations for children by age 7. Practices nationwide are participating through outreach and in-office events to support early detection efforts.
Universal Orthodontic Lab has named Dr Ryo Hamanaka chief clinical officer and head of its Experimental Applications Group, overseeing clinical strategy and development of new orthodontic solutions.
Align Technology awarded $300,000 in research grants to 12 universities worldwide as part of its 15th Annual Research Award Program, supporting orthodontic and dental research across the Americas, Europe, and Asia Pacific.